Abingworth Clinical Co-Development Fund 3 LP is a private equity fund based in Washington, District of Columbia. Its most recent Form D, filed Jun 25, 2025, reports no sales yet. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(c), which permits general advertising to investors verified as accredited. Related persons named in the filing include David Lobe; Robert Rosen; Christina Gibbs.
- Total raised
- $0Cumulative sales reported on Form D
- Investors
- 0
- First sale
- —
- Minimum investment
- None set
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(c)May advertise; investors must be verified as accredited
- Key people and entities
- David Lobe; Robert Rosen; Christina Gibbs
- Latest Form D
- Jun 25, 2025
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about Abingworth Clinical Co-Development Fund 3 LP
What is the minimum investment for Abingworth Clinical Co-Development Fund 3 LP?
Abingworth Clinical Co-Development Fund 3 LP's latest Form D, filed Jun 25, 2025, does not set a minimum investment. Managers can still require one in the offering documents.
Who can invest in Abingworth Clinical Co-Development Fund 3 LP?
Abingworth Clinical Co-Development Fund 3 LP is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(c), so it may advertise, but every investor must be verified as accredited.
How much has Abingworth Clinical Co-Development Fund 3 LP raised?
Abingworth Clinical Co-Development Fund 3 LP's latest Form D, filed Jun 25, 2025, reports no sales yet.
Where is Abingworth Clinical Co-Development Fund 3 LP based?
Abingworth Clinical Co-Development Fund 3 LP is based in Washington, District of Columbia.
Size compared with every private equity fund
This fund hasn't reported any sales yet.
Other funds with the same team
- Carlyle Asset-Backed Income Fund, L.P.$1.5B
- Carlyle Infrastructure Credit Fund II Note Issuer, L.P.$968M
- CDL Offshore Fund (Levered) Feeder, L.P.$743M
- Carlyle Europe Partners VI - EU, S.C.Sp.$666M
- Carlyle European Direct Lending Fund$468M
- Carlyle EDLF Note Issuer, L.P.$344M
- Carlyle Direct Lending Fund (Levered), L.P.$342M
- Abingworth Bioventures 9 LP$320M